Intelligence Platform
Clinical trials, SEC filings,
hedge fund positioning,
and how they connect.
One database, organized by company, updated daily from primary sources. Built for BD, investors, and strategy teams.
$499/mo
Cancel anytime. Access continues through the end of the billing period.
Live Platform Data
On the platform right now, from primary sources.
Updated Aug 10, 2026
Endpoint modifications, enrollment shifts, and status changes detected automatically for every registered trial.
A secondary endpoint, 'Recording and analysis of all identified SAEs and SADEs through 12-months post-procedure', was removed. The primary endpoint 'Analysis of the Proportion of Subjects Receiving a Single Cryoablation Who Are Free From Any Documented Left Atrial Arrhythmia (AF/AFL/AT)' was clarified to specify 'Following the Blanking Period Lasting Longer Than 30 Seconds on a Continuous 24-hour ECG Recording (Holter Monitor)'.
Status: ACTIVE_NOT_RECRUITING → COMPLETED
Completion date: 2026-07-31 → 2027-04-30
Hedge fund ownership disclosures: who's building positions, reducing stakes, or going activist. Cross-referenced with trial events and 8-Ks.
RA Capital Management
SUVRETTA CAPITAL MANAGEMENT, LLC
RA Capital Management
8-K filings classified by type: licensing deals, FDA actions, financing events, and strategic reviews, identified automatically.
Lantheus Holdings, Inc. has entered into a definitive merger agreement to be acquired by Curium US Holdings LLC. Shareholders will receive $102.50 per share in cash and one Contingent Value Right (CVR) for up to an additional $12.00 per share based on commercial milestones. This transaction will result in Lantheus becoming a wholly owned subsidiary of Curium.
Pfizer is reaffirming its fiscal year 2026 financial guidance, including projected revenues between $59.5 billion and $62.5 billion and adjusted diluted EPS in the range of $2.80 to $3.00. This reaffirmation follows the disclosure of a Chief Financial Officer transition announcement and aligns with previously issued guidance.
Genprex, Inc. announced a collaboration with Roche Diagnostics to validate TROP2 and PTEN as biomarkers for patient selection in non-small cell lung cancer (NSCLC) clinical trials. This strategic partnership aims to leverage Roche's assay development expertise and a previously FDA Breakthrough Device Designated TROP2 antibody to refine patient identification, potentially shortening recruitment times and enabling more personalized treatment. Genprex anticipates completing validation studies by late 2026 for subsequent integration into its NSCLC clinical program.
All items link to original SEC documents and registry records on the platform.
Data
Primary sources, all linked.
Every data point traces to the original filing or registry record. No news, no analyst commentary, no third-party data vendors.
ClinicalTrials.gov
450K+ trials. Status, enrollment, endpoints, results, and change tracking. Updated daily.
SEC EDGAR
8-K, 10-K, 10-Q, Form 4, 13D/13G, 13F and more. Parsed and classified. Updated multiple times daily.
Financial Data
Filter companies by market cap, cash, expenses, and more for 500+ biotech companies.
FDA Data
Drug products, patent listings, and exclusivity records. Integrated
app.rxdatalab.com
What you can do
Built for BD, investors, and strategy teams who work from primary sources rather than news and analyst commentary.
Track a company across every source
Trial pipeline, 8-Ks, Regulatory filings, and financials in one view. Every item links to the original source document or registry record.
Monitor trial changes automatically
Daily comparison against ClinicalTrials.gov catches endpoint modifications, enrollment changes, arm updates, and status shifts. Nothing buried in the registry.
See who's building positions in biotech
Fund profiles with full position history and filing records. Multi-fund convergence on the same company. 13D/G cross-referenced with 8-K events and trial milestones.
See live data sample →Search SEC filings by what they mean
8-K filings classified into financing events, FDA actions, clinical results, licensing deals, and strategic reviews. Search by company, date range, or filing type, not just keyword.
See live data sample →Map competitive landscapes
Search by indication and surface every company running trials for that indication or related indications. Overlay financial position and recent trial events across the competitive field.
Organize research with projects and notes
Create projects with company and trial watchlists. Add timestamped notes directly on company and trial pages. Dashboard shows what changed across your coverage since your last session.
Data In Context
Every event, in context.
Financing events, licensing deals, trial changes, and hedge fund moves — overlaid on the quarterly financial timeline for Solid Biosciences Inc. (SLDB). Toggle layers, hover annotations, click any event to see the original source.
Competitive Landscape
Explore the competitive biotech landscape.
Search any indication. We map every industry trial using the NLM's MeSH medical ontology, then overlays institutional ownership, financial position, and recent trial events across the competitive field.
Condition Landscape
Active industry trials per condition. Search any condition on the platform.
Active Sponsors
| Company | Mkt Cap | Trials | Cash | Qtr Exp |
|---|---|---|---|---|
| Legend Biotech Corp LEGN | $4.0B | 1 | — | — |
| Cullinan Therapeutics, Inc. CGEM | $1.1B | 1 | $79M | $57M |
| Autolus Therapeutics plc AUTL | $562M | 1 | $131M | $61M |
| C4 Therapeutics, Inc. CCCC | $412M | 3 | $61M | $34M |
| Caribou Biosciences, Inc. CRBU | $164M | 2 | $12M | $29M |
| Karyopharm Therapeutics Inc. KPTI | $48M | 2 | $91M | $60M |
| Cellectar Biosciences, Inc. CLRB | $20M | 1 | $8M | $6M |
| Senti Biosciences, Inc. SNTI | $11M | 1 | $12M | $12M |
Sample data. Financial data from parsed 10-K/Q filings. Qtr Exp = R&D + G&A per quarter.
Trial monitoring
Trials can quietly change, don't miss it
Daily comparison against ClinicalTrials.gov. Every endpoint modification, enrollment shift, and status change categorized and summarized automatically.
NCT06168409
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
ASTRAZENECA PLC AZN
Enrollment
218
Primary Completion
2025-08
Detected
Aug 7, 2026
Primary endpoint timeframe
+ 1 more change detected
AI Summary
Four new 'OTHER' endpoints were added, measuring Least Square Mean Difference for Change From Baseline in Seated DBP and SBP at Week 4 and Week 8. Additionally, two secondary endpoints, 'Change from baseline in ambulatory 24-hour average DBP' and 'Change from baseline in the average ambulatory daytime average DBP', were updated to include '(mmHg)' in their descriptions. The 'Change from baseline in ambulatory night-time average SBP' secondary endpoint was also updated to include 'LS Means'.
Full change history per trial. Every detection timestamped and linked to the original registry record.
Subscribe to access →Pricing
Simple, transparent pricing.
Individual — Monthly
Billed monthly. Cancel anytime from your account page.
- ✓ Full platform access
- ✓ BioHedge (13D/G fund positioning)
- ✓ Clinical trial change detection
- ✓ 8-K signal detection
- ✓ Competitive landscape mapping
- ✓ Research workspace and notes
Teams & Institutions
Custom pricing
For teams, firms, and institutional users who need multi-seat access, custom coverage, AI Access, API Access, or enterprise billing.
- ✓ Multi-seat access
- ✓ Custom data coverage and exports
- ✓ Invoiced billing and enterprise contracts
- ✓ API access and custom data feeds
- ✓ Dedicated support
What happens after payment?
You'll receive a welcome email with a link to set your password. Access immediately once your password is set.
How do I cancel?
Go to your account page and click "Manage Billing." Access continues through the end of your billing period.
Do you offer trials or demos?
The public pages at app.rxdatalab.com/biohedge and app.rxdatalab.com/strategic-signals show live data and require no login.
Questions or enterprise pricing?
Email [email protected] for team access, institutional pricing, or anything else.
By subscribing you agree to our Terms of Service and Data License Agreement.